• -->

Webinars

The AC Forum Lunch & Learn Webinar Series covers important and timely topics in anticoagulation care. The webinars are presented each month by international experts, and moderated by a multidisciplinary team of AC Forum board members. Each one hour webinar is presented free of charge and is open to all healthcare professionals. All webinars require pre-registration.

Our recorded webinars are available on YouTube. Visit and subscribe to our channel here: https://www.youtube.com/@AnticoagForum.

Continuing Education Credit

Select webinars are eligible for Enduring Continuing Education credit for physicians, nurses, pharmacists, and pharmacy technicians. Look for the “Claim CME” and “Learner Notification” icons!

Register for Upcoming Webinars

Anticoagulants in Older Adults

Tuesday | March 28, 2024 | 12:00pm ET

Join AC Forum for a discussion on the current environment of Anticoagulants in Older Adults. The focus will delve into the publication, Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Additional consideration will be given to supplementary topics, such as fall and bleed risks and strategies for managing them, polypharmacy, anticoagulation management in nursing home settings, navigating anticoagulants with hospice/end of life situations, as well as outcomes from FRAIL-AF and other relevant papers.

Presenters:
Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP (Moderator)
Arthur Allen, PharmD, CACP (Moderator)
Allison Burnett, PharmD, PhC, CACP (Presenter)
Margaret Fang, MD, MPH (Panelist)
Anna L. Parks, MD (Panelist)

Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar

Tuesday | April 30, 2024 | 12:00pm ET

Andexanet alfa is a specific reversal agent approved to reverse the anticoagulant effects of apixaban and rivaroxaban. The Annexa-I trial was stopped early by the DSMB due to better efficacy with andexanet alfa compared with standard of care treatments. This webinar will present key findings from this trial.

Presenters:
Moderator: Jean Connors, MD (Moderator)
Ashkan Shoamanesh, MD (Presenter)
Deborah Siegal, MD, MSc, FRCPC (Panelist)
Jerrold Levy, MD, FAHA, FCCM (Panelist)

Webinar Archive

All webinars are recorded and can be viewed below.

Thrombosis and Antithrombotic Care in the Hispanic Community
March 19, 2024
Presenters: Alfonso Tafur, MD, MS, MBA, Julia Bayadinova, NP, MN, Julia Mulheman, PharmD, CACP
        
A Discussion of the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
February 21, 2024
Presenters: Arthur Allen, PharmD, CACP; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP; Anastasia Armbruster, PharmD, FACC, BCCP; Renato D. Lopes, MD, MHS, PhD
        
Updates from the 2023 ASH Meeting
January 11, 2024
Presenters: Jean Connors, MD (moderator); Naomi Yates, PharmD, BCACP; Hope Pritchett Wilson, MD; Keith R. McCrae, MD; Jordan Schaefer, MD, MSc, FACP
           
Ask the Experts
November 9, 2023
Presenters: Arthur Allen, PharmD, CACP (moderator), Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP (moderator/panelist); Panelists: Geoff Barnes, MD, MSc, Adam Cuker, MD, MS, Bishoy Ragheb, PharmD, BCACP, CACP, Sara Vazquez, PharmD, BCPS, CACP
  
Personalized VTE Risk Prediction in Cancer Patients using Clinical Informatics
October 10, 2023
Ang Li, MD, MS, Kristen Sanfilippo, MD, Jean Connors, MD, Marc Carrier, MD, MSc, FRCPC
           
A Policy Prescription for Reducing Health Disparities— Achieving Pharmacoequity
September 7, 2023
Utibe R. Essien, MD, MPH, Noelle Ryan, PharmD, Arthur Allen, PharmD, CACP, Naomi Yates, PharmD, BCACP
           
2023 ASH Thrombophilia Testing Guideline
August 30, 2023
Stephan Moll, MD, Jean Connors, MD, Surabhi Palkimas, PharmD, Jori May, MD
           
Outpatient Anticoagulation Stewardship: Focusing on DOAC Management Models
July 25, 2023
Katelyn Sylvester, PharmD, BCPS, CACP, Arthur Allen, PharmD, CACP, CDR Andrew Geller, MD, Jean Connors, MD, Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
        
DOACs and Kidney Dysfunction
June 28, 2023
Renato D. Lopes, MD, MHS, PhD, Arthur Allen, PharmD, CACP, Tracy Minichiello, MD
     
Anticoagulation during Pregnancy
May 24, 2023
Maria T. DeSancho, MD, MSc; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP; Naomi Yates, PharmD, BCACP
              
Aspirin De-prescribing and PPI Prescribing: Gastroprotection Among Patients Taking Oral Anticoagulants
April 26, 2023
Jacob Kurlander, MD, MS; Jordan Schaefer, MD, FACP; Arthur Allen, PharmD, CACP; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
  
Under-prescribing of Oral Anticoagulation and Associated Outcomes for Patients with Atrial Fibrillation: A Call to Action
February 28, 2023
Julia Mulheman, PharmD; Naomi Yates, PharmD, BCACP; Sara Vazquez, PharmD, BCPS, CACP
                 
Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials
January 30, 2023
Behnood Bikdeli, MD, MS, Jean Connors, MD, Surabhi Palkimas, PharmD, Geoff Barnes, MD, MSC, Deb Siegal, MD, MSC, FRCPC
        
Venous Thromboembolism Prevention: The Nurse’s Perspective
December 12, 2022
Arthur L. Allen, PharmD, CACP, Elliott Haut, MD, PhD, FACS, Dauryne Shaffer, MSN, RN, CCRN, Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
     
Rheumatic Valve-Associated AF: Selecting the Best Anticoagulant Strategy
October 27, 2022
Geoffrey Barnes, MD, MSc, FACC, FAHA, FSVM; Arthur L. Allen, PharmD, CACP; Stuart J. Connolly, MD
     
Advancing Anticoagulation Stewardship: A Playbook
October 4, 2022
Arthur L. Allen, PharmD, CACP; Allison Burnett, PharmD, PhC, CACP; Scott Kaatz, DO, MSc, FACP, SFHM; Chelsea Lynch, MPH, MSN, RN, CIC, Scott K. Winiecki, MD
           
Health Disparities in PAD: What to Know as an Anticoagulation Provider
September 21, 2022
Foluso Fakorede, MD and Surabhi Palkimas, PharmD
           
New CHEST Guideline: Perioperative Management of Antithrombotic Therapy
September 9, 2022
James D. Douketis, MD, FRCP(C), FCAHS; Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC; Geoff Barnes, MD, MSc; William E. Dager, PharmD, BCPS, MCCM
     
Anticoagulant Treatment of Cerebral Venous Thrombosis – Where are we in 2022?
August 22, 2022
Thalia Field, MD, FRCPC, MHSc; Arthur L. Allen, PharmD, CACP; Deborah Siegal, MD, MSc, FRCPC
           
Unexplained Arterial Thrombosis: Approach to Diagnosis and Treatment
July 20, 2022
Jori May, MD; Arthur L. Allen, PharmD, CACP; Deborah Siegal MD, MSc, FRCPC; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
           
Implementation of Anticoagulation Stewardship Programs: The Future of Anticoagulation Care
June 8, 2022
Dan Budnitz, MD, MPH, CAPT, USPHS; Kathryn Dane, PharmD; Jori May, MD; Michael Streiff, MD, Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP, Scott Kaatz, DO, MSc, FACP, SFHM; Anne Rose, PharmD
           
Filling the Gaps: Transitions of Care in PE Management
April 12, 2022
Allison Burnett, PharmD, PhC, CACP, Vicki McNally, NP, Rachel Rosovsky, MD, MPH, Brandon Hooks, DO, FCCP, FACOI, Geoff Barnes, MD, MSc
        
Lessons Learned from DOAC Claims-based Observational Studies
February 24, 2022
Geoff Barnes, MD, MSc, Wayne Ray, PhD, Katherine Murray, MD, Arthur Allen, PharmD, CACP
        
Perioperative Management of Anticoagulation: Can You Clear My Patient for a Procedure
January 27, 2022
Arthur Allen, PharmD, CACP; Allison Burnett, PharmD, PhC, CACP; Scott Kaatz, DO, MSc, FACP, SFHM; Bishoy Ragheb, PharmD, BCACP, CACP; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
           
Could I Have Prevented a Stroke?
December 16, 2021
April Allen, PharmD, CACP; Danielle Jenkins, RN, BSN; Julia Mulheman, PharmD; Sara Vazquez, PharmD, BCPS, CACP; Terri Wiggins, MS
     
What's New in Antithrombotic Treatment of VTE Disease: ACCP (CHEST) Guidelines Update 2021
November 11, 2021
Geoffrey Barnes, MD, MSc; Deborah Siegal, MD, MSc; Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP; Philip Wells, MD
        
DOACs and Obesity in 2021: Updates from the ISTH SSC Subcommittee on Control of Anticoagulation
September 15, 2021
Arthur Allen, PharmD, CACP, Karlyn Martin, MD, Stephan Moll, MD, Deborah Siegal, MD, MSc, Andrea Van Beek, RN DNP AGPCNP-BC
     
Combination Aspirin & DOAC Therapy Increases Bleeding Risk
July 21, 2021
Arthur Allen, PharmD, CACP, Geoffrey Barnes, MD, MSc, Jordan Schaefer, MD, Andrea Van Beek, DNP, APRN, AGPCNP-BC, CACP
     
Anticoagulation prophylaxis in COVID-19
June 17, 2021
Behnood Bikdeli, MD, MS, Scott Kaatz, DO, MSc, Patrick Lawler, MD, MPH, Tracy Minichiello, MD
     
Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Valvular AFib
May 25, 2021
Arthur Allen, PharmD, CACP, Geoffrey Barnes, MD, MSc, Adam Cuker, MD, MS, Ghadeer Dawwas, MSc, MBA, PhD, Diane Wirth, ANP, CACP
     
New Clinical Guidance for Managing DOACS - The DOAC Playbook
May 5, 2021
Arthur Allen, PharmD, CACP | Jack Ansell, MD, MACP | Sara Vazquez, PharmD, BCPS, CACP | Diane Wirth, ANP CACP
     
Vaccine-Induced Immune Thrombotic Thrombocytopenia: How it Happens and How to Spot It
April 20, 2021
Donald Arnold, MD, MSc, FRCPC | Mark Crowther, MD, MSc, FRCPC | Narayan Nair, MD | Ishac Nazy, PhD | Menaka Pai, MD, MSc, FRCPC | Ted Warkentin, MD, BSc(Med), FRCPC, FACP, FRCP (Edin)
  
Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory from the American Heart Association
March 18, 2021
Tracy Minichiello, MD | Eduardo Sanchez, MD, MHP, FAAFP | Anjail Z. Sharrief, MD, MPH, FAHA | Paul Walker, PharmD | Terri Wiggins, MS | Sara Vazquez, PharmD, BCPS, CACP
     
Peripheral Artery Disease (PAD) and Dual Inhibition Therapy: Vascular Protection in Patients with CAD/PAD
February 16, 2021
Geoffrey Barnes, MD, MSc, Marc Bonaca, MD, MPH, Henry Han, MD, Eva Kline-Rogers, MS, NP, Bishoy Ragheb, PharmD
        
Current Reversal and Treatment Strategies for DOAC-related Bleeding
January 19, 2021
Megan Barra, PharmD, BCPS, BCCCP, Adam Cuker, MD, MS, Scott Kaatz, DO, MSc, Ronni Nemeth, PharmD, CACP, DPLA, Kelly Rudd, PharmD, FCCP, BCPS, CACPP
     
Treatment of Cancer-Associated Venous Thromboembolism (VTE)
December 11, 2020
Marc Carrier, MD, MSc, Nathan Clark, PharmD, Ryan Fleming, PharmD, David Garcia, MD, Tzu-Fei Wang, MD, MPHP
     
2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation
November 18, 2020
Gregory Lip, MD and Tracy Minichiello, MD
  
Anticoagulation Therapy for Left Ventricular Thrombus
October 22, 2020
Ann Marie Navar, MD, PhD and Arthur Allen, PharmD, CACP
  
Post-Discharge Venous Thromboembolism Following Hospital Admission With COVID-19
September 14, 2020
Lara Roberts, MD, MBBS, MRCP and Geoffrey Barnes, MD, MSc
  
COVID-19 AND VTE: Breaking down the Connection
August 4, 2020
Rachel Rosovsky, MD, Edward Ryan, MD, Scott Kaatz, DO, DO, MSc, SFHM
  
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
July 23, 2020
Roxana Mehran, MD, Renato Lopes, MD, PhD, MHS, Dominick Angiolillo, MD, PhD, and Geoff Barnes, MD, MSc
  
COVID-19 Hypercoagulability (McMaster University Chair's Medical Grand Rounds)
May 14, 2020
Ted Warkentin, MD, BSc(Med), FRCPC, FACP, FRCP (Edin) and Mark Crowther, MD MSc
  
Thrombosis in the Hospitalized COVID Positive Patient
April 16, 2020
Tracy Minichiello, MD, Arthur Allen, PharmD, Geoffrey Barnes, MD, Allison Burnett, PharmD, Mark Crowther, MD, Adam Cuker, MD, Bill Dager, PharmD, Steven Deitelzweig, MD, David Garcia, MD
  
Management of Warfarin Patients Who Have Difficulty Getting INR Testing During COVID-19 Pandemic
March 25, 2020
Susan O’Neill, NP, Scott Kaatz, DO, MSc, Arthur Allen, PharmD, Allison Burnett, PharmD, Geoff Barnes, MD, MSc Nate Clark, PharmD, Tracy Minichiello, MD
  
Managing Anticoagulation during the COVID-19 Pandemic - Guidance from the Anticoagulation Forum
March 16, 2020
Arthur Allen, PharmD, Allison Burnett, PharmD, Geoff Barnes, MD, Nate Clark, PharmD, Tracy Minichiello, MD, Sara Vazquez, PharmD, Diane Wirth, ANP
  
The Real-World Use of Combined P-glycoprotein and Moderate CYP3A4 Inhibitors with Rivaroxaban or Apixaban Increases Bleeding
February 27, 2020
Sarah Hanigan, PharmD, Sara Vazquez, PharmD, BCPS, CACP and Geoffrey Barnes, MD, MSc
  
The Impact of Blood Clots and Clotting Disorders on Women’s Health
January 30, 2020
Rachel Rosovsky, MD, Nancy Shapiro, PharmD and Tracy Minichiello, MD
  
Core Elements of Anticoagulation Stewardship Programs
October 30, 2019
Allison Burnett, PharmD, Scott Kaatz, DO, MSc, FACP, SFHM, Tracy Minichiello, MD, Darren Triller, PharmD
  
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant (PAUSE)
September 12, 2019
James Douketis, MD and Nathan Clark, PharmD
  
Periprocedural Bridging in Patients With Venous Thromboembolism: A Systematic Review
August 15, 2019
Christine Baumgartner, MD, MAS and Margaret Fang, MD, MPH
  
Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum
June 20, 2019
Adam Cuker, MD and Allison Burnett, PharmD
  
AUGUSTUS Trial
May 3, 2019
Renato Lopes, MD, PhD
  
Isolated Distal DVT: Selecting the Best Management Strategies
March 19, 2019
Natalie Evans, MD, MS
  
ASH 2018 Guidelines for Management of VTE: Heparin-Induced Thrombocytopenia and Optimal Management of Anticoagulation Therapy
February 20, 2019
Adam Cuker, MD and Daniel Witt, PharmD, FCCP, BCPS, CACP
  
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
January 9, 2019
David Garcia, MD and Vittorio Pengo, MD
  
Evidence-Based Best Practices for Outpatient Management of Warfarin
December 6, 2018
Adam Rose, MD, MSc, FRCPC
  
Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated VTE: Guidance from the SSC of the ISTH
November 6, 2018
Dr. Marc Carrier, MD, MSc, FRCPC
  
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD
October 11, 2018
Geoff Barnes, MD; Scott Damrauer, MD
  
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
July 18, 2018
Suresh Vedantham, MD
  
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
June 6, 2018
  
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
May 9, 2018
Adam Cuker, MD
  
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
March 28, 2018
John Fanikos, RPh, MBA; Paul Dobesh, PharmD, FCCP, BCPS; Curt Mahan, PharmD
  
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS Trail)
February 8, 2018
John Eikelboom, MB, BS
  
HOKUSAI VTE Cancer Trial: Edoxaban for the Treatment of Cancer-Associated VTE
January 9, 2018
David Garcia, MD
  
Using Clinical Order Sets to Integrate Quality Standards into Point of Care
December 15, 2017
Scott Kaatz, DO, MSc, FACP, SFHM; Geoff Barnes, MD, MSc; Eva Kline-Rogers, MS, NP, AACP; Stacy Ellsworth, RN, MSN, CCRC
  
A Multifaceted Intervention to Improve Treatment with Oral Anticoagulants in Atrial Fibrillation (IMPACT-AF): An International, Cluster-Randomised Trial
November 15, 2017
Renato D. Lopes, MD, MHS, PhD
  
Re-Circuit Trial
October 17, 2017
Edward Gerstenfeld, MD
  
Extended Thrombo-prophylaxis with Betrixaban in Acutely Ill Medical Patients
August 16, 2017
C. Michael Gibson, MD
  
Prevention of Thromboembolic Complications in Patients with Superficial-Vein Thrombosis Given Rivaroxaban or Fondaparinux
June 20, 2017
Jan Beyer-Westendorf, MD
  
Einstein Choice Trial
May 23, 2017
Jeff Weitz, MD, PhD
  
Ticagrelor vs. Clopidogrel in Symptomatic Peripheral Artery Disease
March 28, 2017
William Hiatt, MD
  
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
February 28, 2017
C. Michael Gibson, MD
  
Anticoagulant Therapy for Symptomatic Calf DVT (CACTUS)
January 11, 2017
Marc Carrier, MD, MSc; Gregoire Le Gal, MD, PhD
  
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
December 15, 2016
Peter A. Noseworthy, MD; Xiaoxi Yao, PhD, MPH, MS
  
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
October 25, 2016
Jean M. Connors, MD; Megan E. Barra, PharmD; John Fanikos, RPh, MBA
  
Reducing the Hospital Burden of HIT: Impact of an Avoid-Heparin Program
September 29, 2016
William Geerts, MD
  
Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of VTE
August 17, 2016
Maureen Smythe, PharmD; Paul Dobesh, PharmD; Diane Wirth, ANP; Adam Cuker, MD and Jack Ansell, MD
  
NATF Atrial Fibrillation Consensus Document
June 30, 2016
Christian T. Ruff, MD, MPH
  
Effect of Body Weight on the Efficacy and Safety of the DOACs in VTE
May 12, 2016
Francesco Dentali, MD
  
Guidance for the Evaluation and Treatment of Hereditary and Acquired Thrombophilia
March 30, 2016
Scott Stevens, MD
  
Guidance for the Prevention and Treatment of Cancer-Associated VTE
March 3, 2016
David Garcia, MD; Jack Ansell, MD
  
Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment
February 9, 2016
Allison Burnett, PharmD; Sara Vazquez, PharmD; Jack Ansell, MD
  
Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
January 20, 2016
Jack Ansell, MD; Michael Streiff, MD; Mark Crowther, MD
  
The Changing Characteristics of Atrial Fibrillation Patients Treated with Warfarin
December 1, 2015
Eva Kline-Rogers, NP; Geoff Barnes, MD; Scott Kaatz, DO
  
Clinical Monitoring of DOACs: "Site-Level Variation in and Practices Associated with Dabigatran Adherence"
October 20, 2015
Supriya Shore, MD
  
Idarucizumab for Dabigatran Reversal
September 30, 2015
Charles Pollack, Jr., MD; Jeffrey Weitz, MD
  
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
August 25, 2015
James Douketis, MD; David Garcia, MD; Scott Kaatz, DO
  
Clinical Characteristics & Outcomes with Rivaroxaban vs. Warfarin in Patients with NVAF but Underlying Native Mitral and Aortic Valve Disease Participating in the ROCKET AF Trial
June 16, 2015
Richard C. Becker, MD
  
Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial
May 14, 2015
Christopher Granger, MD; Renato Lopes, MD, PhD
  
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation
March 17, 2015
Benjamin Steinberg, MD; Jack Ansell, MD
  
An Evaluation of the Potential Drug Interaction Between Warfarin and Levothyroxine
February 19, 2015
John R. Horn, PharmD; Michele D. Wood, PharmD; Nathan Clark, PharmD; Daniel M. Witt, PharmD
  
Edoxaban vs Warfarin in Patients with Atrial Fibrillation
January 20, 2015
Robert Giugliano, MD; Christian Ruff, MD, MPH
  
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
November 20, 2014
Jeffrey S. Dlott, MD
  
Patient Webinar - DVT and PE Discussion in Honor of World Thrombosis Day
October 16, 2014
Stephan Moll, MD
  
Antibiotic Interaction with Warfarin in the Ambulatory Setting
September 18, 2014
Nathan Clark, PharmD; Adam Cuker, MD; Scott Kaatz, DO, MSc
  
A Review of RE-COVER I and II: FDA Approves use of Dabigatran for treatment of acute VTE
June 19, 2014
Samuel Z. Goldhaber, MD; Adam Cuker, MD; Scott Kaatz, DO, MSc
  
Compression Stockings to Prevent Post-thrombotic Syndrome: A Randomized Placebo-controlled Trial
May 15, 2014
Susan R. Kahn, MD, MSc
  
Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic
April 16, 2014
Jenny Lopez, MD, MPH, MDiv; Lynn B. Oertel, MS, ANP; Scott Kaatz, DO, MSc
  
Anticoagulation Centers of Excellence: A Case-Based Demonstration
March 20, 2014
Daniel M. Witt, PharmD, FCCP, BCPS, CACP; Arthur Allen, PharmD, CACP; Allison Burnett, PharmD, PhC, CACP; Elaine Whalen, MBA
  
CLOTS3 Trial: AC Forum and Thrombosis Canada
September 19, 2013
Professor Martin Dennis
  
FDA Postmarketing Report on Dabigatran
July 18, 2013
Mary Ross Southworth, PharmD; Marsha E. Reichman, PhD; Ellis F. Unger, MD